With Aduhelm Out Of The Gate, Biogen Focuses On Clearing Commercial Bottlenecks
Executive Summary
PET scans and CSF testing to confirm the presence of amyloid beta, and reimbursement, are expected to be early hurdles for launching aducanumab in Alzheimer's.